Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AMLX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
+133%
0.31
vs -0.93
Q3.23
+133%
0.3
vs -0.92
Q4.23
+111%
0.07
vs -0.65
Q1.24
N/A
-0.46
vs 0.02
Q2.24
N/A
-0.73
vs 0.31
Q3.24
N/A
-0.53
vs 0.3
Q4.24
N/A
-0.55
vs 0.07
Q1.25
N/A
-0.42
vs -0.46
Q2.25
N/A
-0.44
vs -0.73
Q3.25
N/A
-0.45
vs -0.53
Sales Growth
YoY
Current
Estimates
Q2.23
NA
98.2M vs NA
Q3.23
+29666%
102.7M vs 345K
Q4.23
+396%
108.4M vs 21.9M
Q1.24
+24%
88.6M vs 71.4M
Q2.24
-101%
-1023000.00 vs 98.2M
Q3.24
-100%
416K vs 102.7M
Q4.24
-101%
-665000.00 vs 108.4M
Q1.25
-100%
NA vs 88.6M
Q2.25
+5225%
52.4M vs -1023000
Q3.25
+11331%
47.6M vs 416K
Return on Equity
QoQ
Q2.23
+6%
0.06
vs 0
Q3.23
+5%
0.05
vs 0.06
Q4.23
+1%
0.01
vs 0.05
Q1.24
-37%
-0.37
vs 0.01
Q2.24
-28%
-0.28
vs -0.37
Q3.24
-37%
-0.37
vs -0.28
Q4.24
-23%
-0.23
vs -0.37
Q1.25
-18%
-0.18
vs -0.23
Institutionnal Ownership
QoQ
Q2.23
170
170
vs 164
4%
Q3.23
189
189
vs 170
11%
Q4.23
206
206
vs 189
9%
Q1.24
177
177
vs 206
-14%
Q2.24
128
128
vs 177
-28%
Q3.24
116
116
vs 128
-9%
Q4.24
132
132
vs 116
14%
Q1.25
136
136
vs 132
3%
globenewswire.com
10 hours ago
Quote Panel
Key Metrics
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.11Â ( -2.02%)
After-hours 5.30$-0.03 (-0.47%)
Relative Strenght
96
Volume Buzz
5%
Earning Acce
Yes
Dist 52w H.
27%Relative Strength
AMLX
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
NaN%2026-Revenue
-219%2026-EPS
100%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
10.00(87.62%)
Number of analyst
1
Last analyst upgrade/downgrade
Bank of America Securities
upgradePrevious: Not converted
2024-10-23
Now: Buy
